MAP BioPharma responds to Health Select Committee enquiry on Brexit

MAP BioPharma has submitted a written response to the Commons Health Select Committee enquiry on Brexit – medicines, medical devices and substances of human origin.

The inquiry aims to examine the regulatory arrangements needed to guarantee the safe supply of such products following the UK’s withdrawal from the EU, including any opportunities/trade-offs, transitional arrangements, radioisotopes supply, and research and development implications.

Please click here to read MAP BioPharma’s full response to the enquiry.

Tagged with

Published 24. October 2017 in News UK